Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEEp OLE long-term LP352 extension study in developmental and epileptic encephalopathies
jRCT2031260149Phase 3Recruiting
- Sponsor
- Lundbeck
- Start
- May 2026
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of bexicaserin in epileptic encephalopathy, Dravet syndrome and Lennox-Gastaut syndrome (LGS), sponsored by Lundbeck. Primary endpoint: Treatment-emergent adverse events and serious adverse events. Started May 2026; status: recruiting.
02
Drugs
bexicaserin
03
Conditions
epileptic encephalopathyDravet syndromeLennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on jRCT2031260149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260149.